Posts

Showing posts with the label Splenomegaly market forecast

Splenomegaly – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Splenomegaly is a condition characterized by an enlarged spleen. The "gold-standard" definition of splenomegaly is measuring the spleen's weight, as a normal adult spleen weighs between 50-250 grams, and this decreases with age. There are various potential causes of splenomegaly, including liver disease, hematologic malignancies, venous thrombosis, splenic congestion, cytopenias, splenic sequestration, infections, connective tissue diseases, infiltrative disorders, focal lesions, and others. Clinical signs of splenomegaly include a rapid drop in hemoglobin, leading to hypovolemic shock and death. Splenomegaly can be classified based on its pathophysiologic mechanism: Congestive, by pooled blood (e.g., portal hypertension); infiltrative, by invasion by cells foreign to the splenic environment (e.g., metastases, myeloid neoplasms lipid storage diseases), Immune, by an increase in immunologic activity and subsequent hyperplasia (e.g., endocarditis, sarcoidosis, rheumatoi...

Splenomegaly – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
 Splenomegaly is a condition characterized by an enlarged spleen. The "gold-standard" definition of splenomegaly is measuring the spleen's weight, as a normal adult spleen weighs between 50-250 grams, and this decreases with age. There are various potential causes of splenomegaly, including liver disease, hematologic malignancies, venous thrombosis, splenic congestion, cytopenias, splenic sequestration, infections, connective tissue diseases, infiltrative disorders, focal lesions, and others. Clinical signs of splenomegaly include a rapid drop in hemoglobin, leading to hypovolemic shock and death. It is classified according to its pathophysiologic mechanism: Congestive, by pooled blood (e.g., portal hypertension); Immune, by an increase in immunologic activity and subsequent hyperplasia (e.g., endocarditis, rheumatoid arthritis), sarcoidosis, infiltrative, by invasion by cells foreign to the splenic environment (e.g., metastases, myeloid neoplasms lipid storage diseases),...